title: From IgE to Omalizumab.
abstract: IgE is the least abundant Ig isotype, yet it plays a critical role in allergic reactions and host protection from helminth infection. Although IgE was discovered 50 years ago, the ultimate evidence for its role in human allergic diseases was obtained by the efficacy of anti-IgE therapy in many clinical trials on asthma and other allergic diseases. Beginning from the discovery of IgE 50 y ago, followed by studies of IgE receptors and activation mechanisms, this review provides a historic perspective of allergy research that has led to the development of anti-IgE therapy and other strategies targeting IgE and its receptors. Current IgE studies toward future precision medicine are also reviewed.
authors.affiliation: Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037; toshi@lji.org.|Department of Dermatology, University of California San Diego School of Medicine, La Jolla, CA 92093.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kawakami
authors.affiliation: INSERM Unité 1149, Centre de Recherche sur I'Inflammation, 75018 Paris, France.|CNRS Equipe de Recherche Labellisée 8252, 75018 Paris, France.|Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Site Xavier Bichat, 75018 Paris, France; and.|Inflamex Laboratory of Excellence, Xavier Bichat Site, 75018 Paris, France.
authors.forename: Ulrich
authors.identifier: 0000-0002-2661-2983
authors.initials: U
authors.lastname: Blank
mesh_terms: D001249:Asthma / Q000188:drug therapy* / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology*; D000069444:Omalizumab / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000069444:Omalizumab; D007073:Immunoglobulin E